98%
921
2 minutes
20
Background And Objective: Salvage robotic-assisted radical prostatectomy (S-RARP) is one option for treating patients with recurrent prostate cancer after prostate-preserving primary therapy. However, the tissue damage, anatomical distortion, and lack of surgical landmarks caused by the primary treatment still constitute a major challenge to surgeons. We aim to report the experience of our group on S-RARP.
Methods And Surgical Procedure: A retrospective multicentric study including data from nine centers from the European Association of Urology Robotic Urology Section Scientific Working Group was conducted. Overall, 397 patients who underwent S-RARP from 2008 to 2023 were included and divided into three groups (primary radiation therapy [RT], whole gland [WG] ablation, and focal gland [FG] ablation). The primary endpoints were the safety and feasibility of S-RARP. The secondary endpoints were the comparison of functional and oncological outcomes among different primary therapies.
Key Findings And Limitations: The median (interquartile range) follow-up periods for RT, FG ablation, and WG ablation were 38 (19-73), 20 (10-37), and 24 (16-38) mo, respectively (p < 0.001). Only four patients (1%) had intraoperative complications and <2% had Clavien grade ≥3 after surgery. The 5-yr cumulative incidence rates of biochemical recurrence were 35%, 45%, and 23% for RT, FG ablation, and WG ablation, respectively (p = 0.3). The 3-yr cumulative incidence rates of continence were 67%, 92%, and 71% for RT, FG ablation, and WG ablation, respectively (p < 0.001). The 5-yr cumulative incidence rates of potency were 16%, 11%, and 5.3% (p = 0.2), while the overall survival rates at 5 yr were 95%, 94%, and 100% for RT, FG ablation, and WG ablation, respectively (p = 0.7).
Conclusions: S-RARP is safe and feasible with very low rates of perioperative complications. Functional outcomes in patients undergoing S-RARP are inferior to outcomes at primary surgery and demand highly skilled surgical expertise. Patients should be counseled carefully that the functional outcomes are inferior to those at primary surgery.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.eururo.2025.03.009 | DOI Listing |
Investig Clin Urol
September 2025
Department of Urology, University of Washington, Seattle, WA, USA.
Vesicourethral anastomotic stenosis (VUAS) is a challenging complication following radical prostatectomy with incidence ranging between, and sometimes exceeding, 1.4%-4.8%.
View Article and Find Full Text PDFScand J Urol
September 2025
Department of Urology, Oslo University Hospital, Oslo, Norway.
Objective: To evaluate oncological and functional outcomes after salvage robotic-assisted laparoscopic radical prostatectomy (sRALP).
Material And Methods: We included 60 patients, consecutively treated with sRALP for radiorecurrent prostate cancer (PCa) at Oslo University Hospital (OUS). Data were collected from our PCa registry and electronic patient journal (EPJ).
Urol Oncol
August 2025
Department of Urology, Houston Methodist Hospital, Houston, TX. Electronic address:
Introduction/background: For men with local recurrence of prostate cancer following radiotherapy, salvage radical prostatectomy (SRP) may be considered. However, SRP is associated with increased risk of surgical complications and patient selection is critical. To quantify this contemporary risk and identify predictive factors, we performed a retrospective cohort study utilizing the NSQIP targeted radical prostatectomy (RP) dataset.
View Article and Find Full Text PDFUpdates Surg
August 2025
Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Here, we present the case of a 27-year-old male with a known history of Von Hippel Lindau (vHL) syndrome who was found to have a recurrent paraganglioma in the retrocaval space after laparoscopic right partial adrenalectomy at age 16. He was referred for consideration of a minimally invasive approach to resection. This is particularly important in vHL patients as they are at a high risk of recurrence and need for additional surgical interventions over the course of their lifetime.
View Article and Find Full Text PDFJ Clin Med
August 2025
UT MD Anderson Cancer Center, Houston, TX 77030, USA.
Transoral robotic surgery (TORS) has advanced treatment for complex oropharyngeal cancers (OPC) by offering minimally invasive, precise approaches, initially for ablative and now for reconstructive procedures. This review examines TORS in OPC reconstruction, comparing it to traditional methods and presenting a TORS case with free flap reconstruction in recurrent OPC. A PubMed review assessed TORS-based reconstruction outcomes, technical challenges, and innovations.
View Article and Find Full Text PDF